Lista de obras - Mark A Boyd - Dominio Público Uruguay

A Randomized Study of Pharmacokinetics, Efficacy, and Safety of 2 Raltegravir Plus Atazanavir Strategies in ART-Treated Adults

article

A comparison of computational models with and without genotyping for prediction of response to second-line HIV therapy.

artículo científico publicado en 2014

A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection.

artículo científico publicado en 2014

A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study).

artículo científico publicado en 2008

Addressing smoking among people living with HIV: a cross-sectional survey of Australian HIV health practitioners’ practices and attitudes

article

Ageing and long-term CD4 cell count trends in HIV-positive patients with 5 years or more combination antiretroviral therapy experience

artículo científico publicado en 2012

Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study

artículo científico publicado en 2016

Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature

artículo científico publicado en 2013

Antiretroviral roll-out: the problem of second-line therapy

artículo científico publicado en 2009

Antiretroviral therapy: dolutegravir sets SAIL(ING).

artículo científico publicado en 2013

Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines

artículo científico publicado en 2017

Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018.

artículo científico publicado en 2018

Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.

artículo científico publicado en 2015

Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard fir

artículo científico publicado en 2016

Body composition substudy of the SECOND-LINE study - Author's reply.

artículo científico publicado en 2017

Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy

artículo científico publicado en 2013

Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapy

artículo científico publicado en 2014

Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).

artículo científico publicado en 2006

CD4(+) T Follicular Helper and IgA(+) B Cell Numbers in Gut Biopsies from HIV-Infected Subjects on Antiretroviral Therapy Are Similar to HIV-Uninfected Individuals

artículo científico publicado en 2016

CD4:CD8 ratio comparison between cohorts of HIV-positive Asians and Caucasians upon commencement of antiretroviral therapy

artículo científico publicado en 2017

Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study

artículo científico publicado en 2017

Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz

artículo científico publicado en 2006

Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era.

scientific article published on January 2010

Clinical research in low- and middle-income countries

artículo científico publicado en 2009

Co-infections in an HIV-infected man from Malawi.

artículo científico publicado en 2007

Combination ART: are two drugs as good as three?

artículo científico publicado en 2018

Considering the benefits of disease-specific interventions on overall public health

artículo científico publicado en 2008

Creation of a drug fund for post-clinical trial access to antiretrovirals

artículo científico publicado en 2004

Current and future management of treatment failure in low- and middle-income countries

artículo científico publicado en 2010

Currently available medications in resource-rich settings may not be sufficient for lifelong treatment of HIV.

artículo científico publicado en 2013

Deferred modification of antiretroviral regimen following documented treatment failure in Asia: results from the TREAT Asia HIV Observational Database (TAHOD).

artículo científico publicado en 2009

Determinants of viremia copy-years in people with HIV/AIDS after initiation of antiretroviral therapy

scientific article published on May 2014

Dolutegravir--a promising antiretroviral in development

artículo científico publicado en 2011

Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens

artículo científico publicado en 2007

Early initiation of antiretroviral therapy for people newly diagnosed with HIV infection in Australia: trends and predictors, 2004–2015

article

Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy.

artículo científico publicado en 2008

Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysi

artículo científico publicado en 2017

Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis

artículo científico publicado en 2016

Evidence and policy in the globalized response to AIDS

article

Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression

artículo científico publicado en 2009

HIV care in Yangon, Myanmar; successes, challenges and implications for policy.

artículo científico publicado en 2017

HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy

artículo científico publicado en 2013

Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort

artículo científico publicado en 2004

Improvements in antiretroviral therapy outcomes over calendar time

artículo científico publicado en 2009

Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009.

artículo científico publicado en 2005

Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role?

artículo científico publicado en 2007

Industry and bioethics: what price the relationship?

artículo científico publicado en 2006

Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial

artículo científico publicado en 2011

Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis

artículo científico publicado en 2015

Is it time to rethink syphilis control?

artículo científico publicado en 2014

Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide

artículo científico publicado en 2003

Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients

artículo científico publicado en 2004

Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials

artículo científico publicado en 2010

Long-acting injectable ART: next revolution in HIV?

article

Long-term survival in HIV positive patients with up to 15 Years of antiretroviral therapy

artículo científico publicado en 2012

Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosis

artículo científico publicado en 2006

Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial

artículo científico publicado en 2017

Metastatic adenocarcinoma mimicking 'target sign' of cerebral tuberculosis

artículo científico publicado en 2006

Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial

artículo científico publicado en 2014

Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration

artículo científico publicado en 2017

Novel antiretroviral agents and universal access to HIV care

artículo científico publicado en 2015

Operational research in HIV priority areas: the African way

article

Optimisation of HIV care and service delivery: doing more with less

artículo científico publicado en 2012

Overly Optimistic Forecasts for the Impact of Treatment of HIV Prevention for Men Who Have Sex With Men

article

Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot study

artículo científico publicado en 2012

Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients

artículo científico publicado en 2003

Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects

artículo científico publicado en 2003

Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection

artículo científico publicado en 2015

Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps

article

Rates and factors associated with major modifications to first-line combination antiretroviral therapy: results from the Asia-Pacific region

artículo científico publicado en 2013

Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience

article

Recent trends in early stage response to combination antiretroviral therapy in Australia

artículo científico publicado en 2014

Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir

artículo científico publicado en 2006

Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy

artículo científico publicado en 2018

Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001 ⬇️

artículo científico publicado el 17 de octubre de 2003

SPRING-2 the future of antiretroviral therapy

artículo científico publicado en 2013

STRETCHing delivery of HIV health services

article

Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research

artículo científico publicado en 2007

Sexual transmission of HIV and the law: an Australian medical consensus statement.

artículo científico publicado en 2016

Smoking and HIV: what are the risks and what harm reduction strategies do we have at our disposal?

article

Tenofovir alafenamide: safer, but questions remain

artículo científico publicado en 2016

The LATTE study: a provocative brew

artículo científico publicado en 2015

The Sydney Declaration: a call to scale up research

artículo científico publicado en 2007

The clinical utility of the urine-based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: an observational study

artículo científico publicado en 2017

The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool

artículo científico publicado en 2011

The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa

artículo científico publicado en 2013

The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity

artículo científico publicado en 2006

Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke

artículo científico publicado en 2017

Towards a universal second-line fixed-dose combination ART.

artículo científico publicado en 2017

Treatment efficacy of azithromycin 1 g single dose versus doxycycline 100 mg twice daily for 7 days for the treatment of rectal chlamydia among men who have sex with men - a double-blind randomised controlled trial protocol

artículo científico publicado en 2017

Vaporised nicotine and tobacco harm reduction for addressing smoking among people living with HIV: A cross-sectional survey of Australian HIV health practitioners' attitudes.

artículo científico publicado en 2017

Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012).

artículo científico publicado en 2006

Which HIV patients should be screened for osteoporosis: an international perspective.

artículo científico publicado en 2016

Lista de obras de Mark A Boyd

A Randomized Study of Pharmacokinetics, Efficacy, and Safety of 2 Raltegravir Plus Atazanavir Strategies in ART-Treated Adults

A comparison of computational models with and without genotyping for prediction of response to second-line HIV therapy.

A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection.

A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study).

Addressing smoking among people living with HIV: a cross-sectional survey of Australian HIV health practitioners’ practices and attitudes

Ageing and long-term CD4 cell count trends in HIV-positive patients with 5 years or more combination antiretroviral therapy experience

Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study

Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature

Antiretroviral roll-out: the problem of second-line therapy

Antiretroviral therapy: dolutegravir sets SAIL(ING).

Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines

Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018.

Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.

Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard fir

Body composition substudy of the SECOND-LINE study - Author's reply.

Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy

Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapy

Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).

CD4(+) T Follicular Helper and IgA(+) B Cell Numbers in Gut Biopsies from HIV-Infected Subjects on Antiretroviral Therapy Are Similar to HIV-Uninfected Individuals

CD4:CD8 ratio comparison between cohorts of HIV-positive Asians and Caucasians upon commencement of antiretroviral therapy

Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study

Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz

Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era.

Clinical research in low- and middle-income countries

Co-infections in an HIV-infected man from Malawi.

Combination ART: are two drugs as good as three?

Considering the benefits of disease-specific interventions on overall public health

Creation of a drug fund for post-clinical trial access to antiretrovirals

Current and future management of treatment failure in low- and middle-income countries

Currently available medications in resource-rich settings may not be sufficient for lifelong treatment of HIV.

Deferred modification of antiretroviral regimen following documented treatment failure in Asia: results from the TREAT Asia HIV Observational Database (TAHOD).

Determinants of viremia copy-years in people with HIV/AIDS after initiation of antiretroviral therapy

Dolutegravir--a promising antiretroviral in development

Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens

Early initiation of antiretroviral therapy for people newly diagnosed with HIV infection in Australia: trends and predictors, 2004–2015

Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy.

Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysi

Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis

Evidence and policy in the globalized response to AIDS

Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression

HIV care in Yangon, Myanmar; successes, challenges and implications for policy.

HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy

Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort

Improvements in antiretroviral therapy outcomes over calendar time

Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009.

Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role?

Industry and bioethics: what price the relationship?

Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial

Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis

Is it time to rethink syphilis control?

Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide

Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients

Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials

Long-acting injectable ART: next revolution in HIV?

Long-term survival in HIV positive patients with up to 15 Years of antiretroviral therapy

Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosis

Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial

Metastatic adenocarcinoma mimicking 'target sign' of cerebral tuberculosis

Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial

Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration

Novel antiretroviral agents and universal access to HIV care

Operational research in HIV priority areas: the African way

Optimisation of HIV care and service delivery: doing more with less

Overly Optimistic Forecasts for the Impact of Treatment of HIV Prevention for Men Who Have Sex With Men

Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot study

Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients

Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects

Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection

Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps

Rates and factors associated with major modifications to first-line combination antiretroviral therapy: results from the Asia-Pacific region

Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience

Recent trends in early stage response to combination antiretroviral therapy in Australia

Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir

Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy

Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001 ⬇️

SPRING-2 the future of antiretroviral therapy

STRETCHing delivery of HIV health services

Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research

Sexual transmission of HIV and the law: an Australian medical consensus statement.